Merck KGaA stock (DE0006599905): Latest developments and business overview

Merck KGaA maintains its position as a diversified player in healthcare, life sciences, and electronics, with recent focus on strategic growth initiatives. The company reported solid performance in its core segments during the first quarter of 2026, according to Merck IR as of 04/30/2026. Shares have shown resilience, trading around 170 EUR on the Frankfurt exchange recently.

As of: 12.05.2026

By the editorial team – specialized in equity coverage.

Merck KGaA: core business model

Merck KGaA operates through three main pillars: Healthcare, Life Science, and Electronics. The Healthcare division focuses on innovative therapies in oncology and neurology, including the blockbuster drug Mavenclad for multiple sclerosis. Life Science provides tools and services for biotech research, while Electronics supplies materials for semiconductors and displays. This diversified model reduces sector-specific risks and taps into high-growth areas like precision medicine and chip manufacturing.

The company's strategy emphasizes R&D investment, with over 2.5 billion EUR allocated annually as reported in the 2025 full-year results published 03/06/2026, per Merck IR as of 03/06/2026. Merck KGaA distinguishes itself from US-based Merck & Co. (MRK), maintaining separate operations despite similar naming.

Main revenue and product drivers for Merck KGaA

Pharmaceuticals remain a top driver, generating about 45% of group sales, led by oncology products like Tepmetko and the fertility drug Gonal-f. In Q1 2026, Healthcare sales rose 8% year-over-year to 2.1 billion EUR, driven by pipeline advancements, according to the quarterly report dated 04/30/2026 on the IR site. Life Science benefits from demand in bioprocessing, with tools for mRNA vaccine production gaining traction post-pandemic.

Electronics, contributing 30% of revenue, supplies liquid crystals and OLED materials critical for displays and semiconductors. Sales in this segment grew 12% in Q1 2026 amid global chip shortages easing. For US investors, Merck KGaA's exposure to the semiconductor supply chain links it to major players like Nvidia and TSMC.

Industry trends and competitive position

The global pharma market is projected to grow at 6% CAGR through 2030, per IQVIA as of 01/2026, with oncology and neurology as key areas. Merck KGaA competes with Roche, Novartis, and Bayer in Europe, while its Electronics unit rivals Japan's JSR and Sumitomo Chemical. Strong patent portfolio with 20,000+ active patents bolsters its moat.

In life sciences, demand for single-use bioprocessing systems positions Merck ahead, capturing share from Thermo Fisher. US market relevance stems from EMD Serono subsidiary, providing direct access to American biotech hubs.

Why Merck KGaA matters for US investors

Merck KGaA offers US investors diversification beyond domestic names, with ADRs available OTC (MKKGY) and ties to the US via 20%+ revenue from North America. Its electronics materials support US tech giants, benefiting from AI and EV booms. Listing on Xetra and Frankfurt provides liquidity, with volatility often lower than pure pharma peers.

Recent financial performance

Full-year 2025 sales reached 23.2 billion EUR, up 5% organically, with EBITDA pre margin at 28%, as per the annual report published 03/06/2026. Q1 2026 showed continued momentum, with group sales up 7% to 5.8 billion EUR. Free cash flow stood at 3.1 billion EUR for 2025, supporting dividends and buybacks.

Conclusion

Merck KGaA demonstrates resilience across its diversified segments, with strong Q1 2026 results underscoring execution on growth priorities. Exposure to high-demand areas like oncology and semiconductors supports long-term potential, while R&D focus positions it well in competitive markets. US investors gain international diversification through its North American footprint and tech linkages.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.